Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.

ClinicalTrials.gov ID: NCT00315705

Public ClinicalTrials.gov record NCT00315705. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 6:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Dose-Escalation Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Pediatric Patients With Refractory or Relapsed Acute Leukemias.

Study identification

NCT ID
NCT00315705
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Genzyme, a Sanofi Company
Industry
Enrollment
50 participants

Conditions and interventions

Interventions

  • clofarabine Drug
  • Etoposide Drug
  • Cyclophosphamide Drug

Drug

Eligibility (public fields only)

Age range
1 Year to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2006
Primary completion
Apr 30, 2010
Completion
Apr 30, 2010
Last update posted
Apr 13, 2014

2006 – 2010

United States locations

U.S. sites
13
U.S. states
11
U.S. cities
12
Facility City State ZIP Site status
Children's Hospital of Alabama Birmingham Alabama
Children's Hospital of Los Angeles Los Angeles California
Rady Children's Hospital San Diego California
Connecticut Children's Medical Center Hartford Connecticut
Children's Memorial Hospital Chicago Illinois
St. Vincent Children's Hospital Indianapolis Indiana
Dana Farber Cancer Institute Boston Massachusetts
Children's Hospital of Michigan Detroit Michigan
Memorial Sloan-Kettering Cancer Center New York New York
New York School of Medicine New York New York
St. Jude Children's Research Hospital Memphis Tennessee
University of Texas MD Anderson Cancer Center Houston Texas
Seattle Children's Hospital Seattle Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00315705, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 13, 2014 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00315705 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →